UT MD Anderson and P-Cure collaborate to advance first compact upright dual-modality proton and helium ion therapy platform
The University of Texas MD Anderson Cancer Center and P-Cure Ltd. today announced a strategic alliance to advance the development and clinical validation of a next-generation particle therapy platform designed to deliver both proton and helium ion therapy from a single compact upright treatment system.
The collaboration combines UT MD Anderson's expertise in radiation oncology, particle therapy and translational cancer research...
UT MD Anderson announces historic expansion of cancer care facilities
The University of Texas MD Anderson Cancer Center today announced the historic expansion of its Texas Medical Center (TMC) campus through...
Allison Institute convenes leading scientists and clinicians for fourth annual scientific symposium on frontiers of immunotherapy
Annual meeting focused on immune set points andthe regulatory mechanisms shaping the next generation of cancer immunotherapies
Symposium featured...
New statewide plan aims to eliminate cervical cancer in Texas by 2032
Texas Lone Star Cervical Cancer Elimination Plan unveiled at the CPRIT 2026 Innovations Conference with the support of a statewide coalition
Texas ranks eighth in nation for incidence rate and sixth in nation for mortality rate from cervical cancer
Plan is anchored by three goals: increasing HPV vaccination, improving cervical cancer screening and ensuring appropriate diagnostic follow-up and treatment
On behalf of a statewide coalition...
UT MD Anderson honors visionary leadership of Dr. Peter Pisters following retirement announcement; shares transition plans
The University of Texas MD Anderson Cancer Center today is recognizing the exceptional leadership of Peter WT Pisters, M.D., president, following...
Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy
Patients with metastatic castration-resistant prostate cancer who do not benefit from chemotherapy need more effective treatment options
Phase...
Allison Institute announces appointment of four new members
The James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center today announced the appointment of...
MD Anderson and SOPHiA GENETICS announce strategic collaboration to accelerate AI-driven precision oncology
The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS...
Leading cancer research centers reinforce importance of safe and effective HPV vaccination to prevent cancer
62 NCI-designated cancer centers, leading national organizations and the University of Puerto Rico Comprehensive Cancer Center jointly endorse...
MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies
Agreement focuses on rimiducid, an agent used to activate certain safety switch technologies in cell therapies
Phoenix receives a supply of...